Last updated 16 months ago
Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
30 patients around the world
Available in Mexico
During the proposed treatment, blinatumomab therapy will be assigned as follows:
Blinatumomab 17.5 mcg per day for 2 days, followed by blinatumomab 28 mcg per day for 5 days. Dexamethasone 20 mg will be applied one hour before starting dose.
The immunotherapy will be applied as a 24-hour continuous infusion. The scheduled appointments will be on the initial day of blinatumomab, when the patient will be discharged from hospital and evaluation will be performed on day 10 with bone marrow aspiration and MRD assessment trough next generation flow cytometry. The results will be given at the appointment on day 14, along with an assessment profile for HSCT.
Hospital Universitario Dr. Jose E. Gonzalez
1Research sites
30Patients around the world
This study is for people with
Leukemia
Acute lymphoblastic leukemia
Requirements for the patient
To 60 Years
All Gender
Medical requirements
- Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.MRD detectable in complete response above the limit of quantification according to FCM.Performance status 0-2 on the ECOG scale.No prior organ damage.Having a potential related or unrelated donor.
- Performance status on the ECOG scale greater than 2.HCT-CI greater than 3 points.Patients who do not wish to participate in clinical study.Active central nervous system infiltration CNS3.Active extramedullary disease.Having previously received blinatumomab.Absence of related or unrelated donors.
Sites
Hospital Universitario Dr. José Eleuterio González
Recruiting
SponsorHospital Universitario Dr. Jose E. Gonzalez
Study typeInterventional
Conditions
Acute lymphoblastic leukemia
Requirements
To 60 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06886074
